PROBLEM TO BE SOLVED: To provide a solid pharmaceutical composition of 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobuta-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide and an oral dosage form act as a CXCR2 receptor inhibitor and is useful for treatments of inflammatory, obstructive or allergic symptom and disease, for example a treatment of chronic obstructive pulmonary disease(COPD).SOLUTION: There are solid pharmaceutical composition and an oral dosage form using a choline salt represented by the following formula. There is provided a solid pharmaceutical composition containing an alkalization agent, a precipitation inhibitor and additional pharmaceutically acceptable carrier with the compound.SELECTED DRAWING: None【課題】CXCR2受容体拮抗剤として作用し、炎症性、閉塞性またはアレルギー性症状および疾患の治療、例えば慢性閉塞性肺疾患(COPD)の治療に有用である6-クロロ-3-[2-(1-エチル-プロピルアミノ)-3,4-ジオキソ-シクロブタ-1-エニルアミノ]-2-ヒドロキシ-N-メトキシ-N-メチル-ベンゼンスルホンアミドの固体医薬組成物及び経口投薬剤形の提供。【解決手段】下式で表されるコリン塩を用いた固体医薬組成物及び経口投薬剤形。前記化合物にアルカリ化剤、沈殿阻外剤及び追加医薬上許容しうる担体を含む固体医薬組成物。【選択図】なし
